What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News Atrogi’s ATR-258 breakthrough: muscle-targeted β2-agonist mimics exercise to treat obesity, diabetes, and muscle loss Atrogi’s ATR-258 mimics exercise through skeletal muscle targeting to reduce fat and preserve muscle, redefining obesity and diabetes therapies. bySoujanya RaviJune 23, 2025